DIGITAL HEALTH INTELLIGENCE REPORT COLLECTION
Update your go-to-market strategy to win stakeholder support
Increasing competition, the rising influence and expectations of multiple stakeholders and growing resistance from cash-strapped payers are defining pharma’s go-to-market (GTM) challenge. When is the ideal time to engage with stakeholders? How can value added services differentiate a company’s market position? What role is tiered pricing playing? Which digital tools and strategies are informing GTM approaches?
To develop agile intelligence-led GTM models, turn to Evolving Go-To-Market Strategies, in which senior industry experts reveal the latest thinking and practices for success.
Report Overview
Advanced medical wearables now comprise smart patches, smart rings, smart garments and smart ear buds and the emergence of validated medical-grade technology in consumer devices is seen as critical in delivering the next generation of wearables. Regulators are supportive and payers are seeing the contribution wearables can make to lowering the overall cost of health.
So, how can pharma benefit? In Innovations in Wearables for Digital Health digital health experts review the current wearables sector, examine the technologies that will shape the future and identify the challenges and areas of opportunity for pharma.
Key Therapies Covered
Bavencio (avelumab)
Keytruda (pembrolizumab)
Opdivo (nivolumab)
Tecentriq (atezolizumab)
Imfinzi (durvalumab)
Cabometyx (cabozantinib)
Fotivda (tivozanib)
Inlyta (axitinib)
Lenvima/Kisplyx (lenvatinib)
Sutent (sunitinib)
Votrient (pazopanib)
Afinitor (everolimus)
abexinostat
MK-6482
bempegaldesleukin
Content Highlights
- Subject synopsis
- Research methodology and objectives
- Key insights summary
- Issues and insights
What Our Clients Are Saying
“Excellent”
Director, Medical Affairs, AstraZeneca
“...this report has been very valuable”
Director, Biotech New Product Planning and Drug Delivery, Eli Lilly
Contact Us
Learn more about this report or how we can support you with additional insights. If you are already a client, log in to read the report.
© 2022 FirstWord. All rights reserved | 1140 Avenue of the Americas, 14th Floor, New York, NY 10036
Partial List of Participating KOLs
Deputy Director
Georgetown Lombardi Comprehensive Cancer Center, and the Scholl Professor and vice chair of the Department of Medical Oncology at Georgetown University Medical Center, Georgetown University School of Medicine, Washington, DC
Associate Professor of Oncology
Roswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY
Professor
Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Head of the Medical Oncology Department
Hospital Universitario Central de Asturias, Oviedo, Spain
Professor of Medicine
Head of the SS Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Professor of Oncology and Chief of the Oncology
Clinical and Translational Research Unit at Georges Pompidou Hospital, Paris, France
Our Research
We engage the world’s leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
Our in-house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
View A Full List Of Therapy Trends Reports
FirstWord ExpertViews reports reveal the real-world insights of knowledgeable experts to analyse in detail key commercial and market trends that pharma management needs to understand if they are to effectively respond to critical developments.
Leading KOLS
KOL Answers
Future Focused
What Makes FirstWord’s ExpertViews Reports Different?
Evolving Go-to-Market Strategies
Senior industry experts explore...
Expert Contributors
Relevant to your needs
We don’t waste time telling you what you already know. The tight screening of expert contributors ensures you get new, cutting edge and relevant insights to take your practical knowledge to new levels.
Boardroom ready
This ExpertViews report is supported by an engaging and accessible slide pack that summarises the core of the research and analysis, making key findings easy to share with colleagues and key stakeholders.
Fresh new content
Our reports cover the current developments and trends that will shape future markets and practice, helping you to identify threats and exploit opportunities.
Deep dive
Our research with industry experts results in hundreds of direct quotes, providing you with a first-hand, objective and comprehensive view of key market-shaping issues.
- Paying for Value
- Building on success of value-based approaches in health care
- Drug VBCs are a priority for some payers
- Choosing the right products
- Manufacturer competence needed for VBC
- Choosing the right payer to work with on a VBC
- VBCs can be offered at launch
- Technology is enabling VBCs
- Piloting VBCs
- Choosing the VBCs to publicize
- The challenges in scaling up use of VBCs
Each issue addressed is broken down into the following subsections
- Issue summary
- Questions
- Key insights
- Expert quotes
- Intelligence exhibits
Content Highlights
- Executive level experience in digital health, digital patient services or digital patient support with at least five years of involvement in digital health initiatives.
- At least three years’ experience in the field of digital health, mobile health, or digital capabilities for health.
- Direct experience designing, executing or influencing innovations in wearables for digital health initiatives in the last 18 months.
Early patient engagement
Early payer engagement
Early government/regulator engagement
Personalised engagement across multiple channels
Intensifying competition
Downward pressure on drug prices
Designing innovative GTM strategies for innovative therapies
Additional customer-facing roles
Building cross-functional capabilities
The continuing evolution of GTM strategies
DNA as a data source: GSK’s partnership with 23andMe
MHRA’s innovation task force
Bristol Myers Squibb’s gamble on MyoKardia’s Mavacamten
- What innovative data sources is pharma using to gain a deeper understanding of patient needs?
- What outcome measures are pharma including in their GTM strategies to convey a drug’s value proposition to payers?
- How can pharma engage with regulators early in the development of new treatments as part of their GTM strategy?
- In what ways are pharma using digital channels to reach physicians as part of their GTM strategy?
- In what ways are pharma differentiating their products and support services from the competition?
- What new or innovative strategies are pharma using to price their drugs and what rationale and supporting evidence do they use to justify that price?
- Joel Beilin, Founder and CEO of Global Audiology Consulting, Denmark
- Giovanni Di Sarro, Senior Business Partner of Global Digital Solutions at Lundbeck, Denmark
- Pierre-Alexandre Fournier, Co-founder of Hexoskin, a leading sensor and AI/analytics company for health, research and medicine
- Serkan Oray, Vice President of Devices, Packaging, & Wearable Technologies at UCB, Belgium
- Panos Papakonstantinou, Global Commercial Director of Mobility Solutions at the Novartis Institutes for BioMedical Research (NIBR), Switzerland
- Gergely Vértes, Solution Accelerator Lead and the Wearable Clinical Project Lead in Epilepsy at UCB Bekgium
- Dr. Jian Yang, Senior Director of Digital Health at Eli Lilly and Company, US
- Anonymous, technology leader, multinational biopharmaceutical company
The experts who contributed to this report have been carefully screened to ensure they have direct and relevant subject area experience. Based on frontline knowledge, the actionable insights shared by these experienced marketing and commercial leaders are essential for developing agile GTM strategies that win the support of all stakeholders.
Case studies included: